Epruvy (previously Ranibizumab Midas)
Analogs of Epruvy (previously Ranibizumab Midas)
Find cheaper analogs and generic equivalents for Epruvy (previously Ranibizumab Midas).
Active Ingredient: ranibizumab
Product Overview
About Epruvy (previously Ranibizumab Midas)
Epruvy (previously Ranibizumab Midas) is a medication used for a specific purpose.
What it is used for
This section is not available in the provided information.
How it is used
Ranibizumab Midas is given by intravitreal injection (injection into the vitreous humour, the jelly-like fluid in the eye). It can only be obtained with a prescription and must be given by a qualified eye doctor who is experienced in giving intravitreal injections. Treatment with Ranibizumab Midas is started with one injection every month, with regular checks of the patient’s vision and examination of the back of the eye, until maximum vision is achieved and/or there are no signs of disease activity. The interval between two injections of Ranibizumab Midas into the same eye must be at least four weeks. Treatment with Ranibizumab Midas should be stopped if the patient is not benefitting from it.
How it works
The active substance in Ranibizumab Midas, ranibizumab, is a small piece of a monoclonal antibody. A monoclonal antibody is a type of protein that has been designed to recognise and attach to a specific target (called an antigen) that is found in certain cells in the body. Ranibizumab has been designed to attach to and block a substance called vascular endothelial growth factor A (VEGF-A). VEGF-A is a protein that makes blood vessels grow and leak fluid and blood, damaging the macula. By blocking VEGF-A, ranibizumab reduces the growth of the blood vessels and controls the leakage and swelling.
Active substance: ranibizumab
Visitor ratings
Help others by rating how useful this product page is.
No ratings yet — be the first.
